Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Declares Quarterly Dividend of $0.24

Posted by Brian Himes on Sep 28th, 2026

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) announced a quarterly dividend on Friday, August 28th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.24 per share by the medical equipment provider on Friday, October 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th.

Zimmer Biomet has a payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Zimmer Biomet to earn $8.99 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.7%.

Zimmer Biomet Stock Up 0.0%

Shares of ZBH stock opened at $91.08 on Monday. The company’s fifty day simple moving average is $96.23 and its two-hundred day simple moving average is $91.25. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $106.88. The stock has a market cap of $17.37 billion, a P/E ratio of 22.16, a PEG ratio of 1.72 and a beta of 0.47. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts predict that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZBH. Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Truist Financial boosted their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. Royal Bank Of Canada upped their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. BMO Capital Markets reiterated a “market perform” rating and issued a $96.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $103.00.

Check Out Our Latest Stock Analysis on Zimmer Biomet

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.